AAIPharma appoints Patrick Walsh
pharmafile | September 21, 2010 | Appointment | Manufacturing and Production |Â Â AAIPharma, appointment, manufacturing and productionÂ
Contract manufacturing and drug development services company AAIPharma has appointed Patrick Walsh as its new chief executive.
Walsh has 30 years of pharmaceutical manufacturing experience and joins the company after stints at Kadmus Pharmaceuticals and Gensia Sicor.
Pete Strothman, a principal with Water Street and a member of AAIPharma Services’ board of directors, said: “Pat has an impressive record of consistently leading pharmaceutical businesses to achieve high levels of growth over the course of his career. He is the ideal executive to advance AAIPharma Services forward, as we focus on pursuing growth opportunities through a combination of organic initiatives and strategic acquisitions.
Pat’s core skills of business development, relationship-building, and sales and marketing will contribute significantly to AAIPharma and our goal of building it into the leading provider of pharmaceutical development services.”
Lee Karras, the firm’s president, who led the firm during the search for a new chief executive, will remain in that role and also becomes chief operating officer.
Related Content

Rotzinger launches modular filling and capping platform for over-the-counter products
Rotzinger PharmaPack has launched a new filling and capping platform called VarioFill, designed to handle …

David Wheadon appointed to board of directors at Seaport Therapeutics
This week, Seaport Therapeutics have appointed David Wheadon MD to their board of directors.

Myeloma UK reveals new Director of Research appointment
UK non-profit organisation Myeloma UK has selected Sarah McDonald as its new Director of Research, …






